启动子多态性对IGF-1基因表达的影响及其在大鼠门脉高压性血管病变中作用机制的研究
|
摘要
目的：
1、构建稳定、可靠、符合肝硬化门脉高压疾病自然演变过程的大鼠动物模型，研究该模型肝脏病变和门静脉高压性血管病变的进展情况。
2、研究胰岛素样生长因子1(IGF-1)在肝硬化门脉高压大鼠中的表达改变，探讨IGF-1在肝硬化门脉高压性血管病变中的作用。
3、研究IGF-1基因启动子的多态性，以及启动子的多态性对IGF-1基因表达的影响和在肝硬化门脉高压性血管病变机制中的作用。
方法：
1、应用CCL4(四氯化碳)腹腔注射法制作肝硬化门脉高压性血管病变模型，以HE染色、Masson三色染色、透射电镜、CT扫描观察大鼠肝脏及其门静脉的病变，并测量门静脉压力以了解该模型血液动力学变化情况。
2、应用RT-RealTime-PCR和免疫组织化学检测病变大鼠肝脏组织IGF-1的mRNA和蛋白水平，应用ELISA方法测定病变大鼠血清IGF蛋白的含量水平，并与正常大鼠组相比较。
3、应用序列特异性引物PCR和非对称性PCR扩增肝硬化组大鼠IGF-1基因启动子，应用基因芯片技术检验IGF-1基因启动子多态性。
结果：
1、腹腔注射CCL4后大鼠肝脏组织经HE染色后可见肝小叶结构紊乱，肝小叶重建，纤维组织增生，肝内假小叶广泛形成，同时伴有明显的汇管区纤维组织增生等肝硬化病理表现；门静脉血管内皮细胞呈结节样增生，平滑肌细胞肥大，成纤维细胞和胶原纤维增多；经CT扫描发现肝硬化组和对照组大鼠肝脏体积分别为9741±2715mm~3和12898±3081 mm~3，两组差异有统计学意义；经测压后发现肝硬化组和正常组大鼠门静脉压力分别为7．6±2．6mmHg，12．4±3．6 mmHg，两组间差异有显著性意义。
2、经免疫组化检测两组肝脏组织IGF-1蛋白表达分别为0．40±0．13和0．68±0．19，差异有统计学意义；经RT-Real Time-PCR检测两组肝脏组织IGF-1 mRNA分别为3．95±2．26和6．12±3．14，差异有统计学意义；经ELISA方法测定两组大鼠血清IGF蛋白分别为687±137 ng／ml和919±183 ng／ml，差异有统计学意义；经相关线性分析，肝细胞IGF-1浓度、血清IGF-1浓度以及肝细胞IGF-1 mRNA浓度对门静脉压力值存在负相关。
3、经序列特异性引物PCR和非对称性PCR扩增肝硬化组大鼠I6F-1基因启动子后，基因芯片技术检验IGF-1基因启动子发现，在肝硬化组大鼠，-10位点碱基多态性导致肝脏IGF-1蛋白含量分别为0．44±0．13(AI)和0．34±0．10(AI)，差异有统计学意义；-35位点碱基多态性导致门静脉压力分别为13．0±3．5(mmHg)和9．6±2．6(mmHg)，两组的差异有统计学意义。
结论：
1、CCL4性肝硬化门脉高压血管病变模型稳定、类似人类自然病程；门静脉系统血流动力学改变明显，是研究门脉高压症的理想模型。
2、在肝硬化门脉高压大鼠模型中，随着肝脏体积的不断缩小、门静脉压力的不断升高，肝脏组织及血清IGF-1蛋白和基因转录水平不断下降。IGF-1是肝硬化门脉高压的保护性因子。
3、IGF-1基因启动子区域-10，-35位点碱基的变异可以导致大鼠IGF-1基因启动子活性的改变，从而影响到IGF-1基因的表达改变引起的门脉高压血管病变的变化。IGF-1基因启动子多态性导致不同的个体在肝硬化门脉高压病程中的反应多态性。
OBJECTIVE
1.To construction of a stable,reliable,consistent of natural evolution of rat model withcirrhotic portal hypertension;to study liver lesions and vasculopathy induced by portalhypertension.
2.To study expression change of insulin-like growth factor 1 (IGF-1) in cirrhotic portalhypertension in rats;to explore mechanism of IGF-1 in portal hypertensive vascularlesions.
3.To study promoter polymorphism on IGF- 1 gene and its effect of IGF- 1 gene expression;to study the association between polymorphisms of the insulin growth factor-1 promoterand vasculopathy in rat with portal hypertension.
METHODS
1.To duplicate model of vasculopathy with portal hypertension by intraperitoneal injectionof CCL4;to detect liver lesion and vasculopathy by HE staining,Masson trichrome staining,transmission electron microscopy,CT scanning;to understand hemodynamicchange by portal venous pressure measurements.
2 To detect mRNA and protein level of IGF- 1 in rat liver tissue by RT-Real Time-PCR andimmunohistochemistry;to detect serum IGF protein levels ELISA;and respectivelycompared the results with normal rats.
3.To detect rats IGF-1 gene promoter by application of sequence-specific primer PCR anddissymmetry PCR of cirrhosis rat;to test IGF-1 gene promoter polymorphism byapplication of gene chip technology.
RESULTS
1.After intraperitoneal injection of CCL4,hepatic lobules structure can be seen disorders,reconstruction,fibrous tissue hyperplasia,accompanied by intrahepatic extensiveformation of false lobules by HE staining;vascular endothelial cells of portal veinhyperplasia,smooth muscle cells hypertrophy,fibroblasts and collagen fibers increase;thevolume of rat liver between liver cirrhosis group and control group is separately 9741±2715mm3 and 12898±3081 mm3 by CT scanning,the difference is statisticallysignificant;portal pressure between liver cirrhosis group and normal by manometry in ratsis 7.6±2.6mmHg and 12.9±3.7 mmHg respectively,difference between the two groupswas significant.
2.IGF-1 protein expression of two groups of liver tissue by immunohistochemicaldetection is 0.40±0.13 and 0.68±0.19,and the difference has statistical significance;IGF-1 mRNA of two groups of liver is 3.95±2.26 and 6.12±3.14 By RT-Real Time-PCRDetection,and the difference has statistical significance;serum IGF protein is 687±137ng/ ml and 919±183 ng/ ml Measured by ELISA,and the difference has statisticalsignificance;there is a negative correlation between liver cells IGF-1 concentrations orserum IGF-1 concentration as well as liver cells IGF-1 mRNA concentration and portalvein pressure By the linear analysis.
3.IGF-1 protein content caused different activity of gene promoter by -10 nucleotide polymorphism are 0.44±0.13 (AI) and 0.34±0.10 (AI) by sequence-specific primer PCRand asymmetric PCR and gene chip technology of liver cirrhosis in rats of liver cirrhosis,the difference has statistical significance;portal vein pressure were 13.0±3.5 (mmHg)and 9.6±2.6 (mmHg) caused by -35 nucleotide polymorphism,the difference between thetwo groups has statistical significance
CONCLUTIONS
1.It is a stable model similarly to human natural course of disease established by CCL4which characterized with vasculopathy in portal hypertension;it is an ideal model forstudying portal portal hypertension which has a significant change of vein hemodynamics.
2.The level of IGF-1 protein and gene transcription continues to drop according todeterioration of liver cirrhosis in rat model with cirrhotic portal hypertension.IGF-1 is aprotective factor in cirrhotic portal hypertension.
3.Variation of IGF-1 gene promoter region on -10,-35 base locus can lead to activitychanges of IGF-1 gene promoter,which affect gene expression changes of IGF-1,therebyaffect the vasculopathy in portal hypertension.Polymorphism of IGF-1 gene promoterleads to individual reaction in course of cirrhotic portal hypertension.
1、构建稳定、可靠、符合肝硬化门脉高压疾病自然演变过程的大鼠动物模型，研究该模型肝脏病变和门静脉高压性血管病变的进展情况。
2、研究胰岛素样生长因子1(IGF-1)在肝硬化门脉高压大鼠中的表达改变，探讨IGF-1在肝硬化门脉高压性血管病变中的作用。
3、研究IGF-1基因启动子的多态性，以及启动子的多态性对IGF-1基因表达的影响和在肝硬化门脉高压性血管病变机制中的作用。
方法：
1、应用CCL4(四氯化碳)腹腔注射法制作肝硬化门脉高压性血管病变模型，以HE染色、Masson三色染色、透射电镜、CT扫描观察大鼠肝脏及其门静脉的病变，并测量门静脉压力以了解该模型血液动力学变化情况。
2、应用RT-RealTime-PCR和免疫组织化学检测病变大鼠肝脏组织IGF-1的mRNA和蛋白水平，应用ELISA方法测定病变大鼠血清IGF蛋白的含量水平，并与正常大鼠组相比较。
3、应用序列特异性引物PCR和非对称性PCR扩增肝硬化组大鼠IGF-1基因启动子，应用基因芯片技术检验IGF-1基因启动子多态性。
结果：
1、腹腔注射CCL4后大鼠肝脏组织经HE染色后可见肝小叶结构紊乱，肝小叶重建，纤维组织增生，肝内假小叶广泛形成，同时伴有明显的汇管区纤维组织增生等肝硬化病理表现；门静脉血管内皮细胞呈结节样增生，平滑肌细胞肥大，成纤维细胞和胶原纤维增多；经CT扫描发现肝硬化组和对照组大鼠肝脏体积分别为9741±2715mm~3和12898±3081 mm~3，两组差异有统计学意义；经测压后发现肝硬化组和正常组大鼠门静脉压力分别为7．6±2．6mmHg，12．4±3．6 mmHg，两组间差异有显著性意义。
2、经免疫组化检测两组肝脏组织IGF-1蛋白表达分别为0．40±0．13和0．68±0．19，差异有统计学意义；经RT-Real Time-PCR检测两组肝脏组织IGF-1 mRNA分别为3．95±2．26和6．12±3．14，差异有统计学意义；经ELISA方法测定两组大鼠血清IGF蛋白分别为687±137 ng／ml和919±183 ng／ml，差异有统计学意义；经相关线性分析，肝细胞IGF-1浓度、血清IGF-1浓度以及肝细胞IGF-1 mRNA浓度对门静脉压力值存在负相关。
3、经序列特异性引物PCR和非对称性PCR扩增肝硬化组大鼠I6F-1基因启动子后，基因芯片技术检验IGF-1基因启动子发现，在肝硬化组大鼠，-10位点碱基多态性导致肝脏IGF-1蛋白含量分别为0．44±0．13(AI)和0．34±0．10(AI)，差异有统计学意义；-35位点碱基多态性导致门静脉压力分别为13．0±3．5(mmHg)和9．6±2．6(mmHg)，两组的差异有统计学意义。
结论：
1、CCL4性肝硬化门脉高压血管病变模型稳定、类似人类自然病程；门静脉系统血流动力学改变明显，是研究门脉高压症的理想模型。
2、在肝硬化门脉高压大鼠模型中，随着肝脏体积的不断缩小、门静脉压力的不断升高，肝脏组织及血清IGF-1蛋白和基因转录水平不断下降。IGF-1是肝硬化门脉高压的保护性因子。
3、IGF-1基因启动子区域-10，-35位点碱基的变异可以导致大鼠IGF-1基因启动子活性的改变，从而影响到IGF-1基因的表达改变引起的门脉高压血管病变的变化。IGF-1基因启动子多态性导致不同的个体在肝硬化门脉高压病程中的反应多态性。
OBJECTIVE
1.To construction of a stable,reliable,consistent of natural evolution of rat model withcirrhotic portal hypertension;to study liver lesions and vasculopathy induced by portalhypertension.
2.To study expression change of insulin-like growth factor 1 (IGF-1) in cirrhotic portalhypertension in rats;to explore mechanism of IGF-1 in portal hypertensive vascularlesions.
3.To study promoter polymorphism on IGF- 1 gene and its effect of IGF- 1 gene expression;to study the association between polymorphisms of the insulin growth factor-1 promoterand vasculopathy in rat with portal hypertension.
METHODS
1.To duplicate model of vasculopathy with portal hypertension by intraperitoneal injectionof CCL4;to detect liver lesion and vasculopathy by HE staining,Masson trichrome staining,transmission electron microscopy,CT scanning;to understand hemodynamicchange by portal venous pressure measurements.
2 To detect mRNA and protein level of IGF- 1 in rat liver tissue by RT-Real Time-PCR andimmunohistochemistry;to detect serum IGF protein levels ELISA;and respectivelycompared the results with normal rats.
3.To detect rats IGF-1 gene promoter by application of sequence-specific primer PCR anddissymmetry PCR of cirrhosis rat;to test IGF-1 gene promoter polymorphism byapplication of gene chip technology.
RESULTS
1.After intraperitoneal injection of CCL4,hepatic lobules structure can be seen disorders,reconstruction,fibrous tissue hyperplasia,accompanied by intrahepatic extensiveformation of false lobules by HE staining;vascular endothelial cells of portal veinhyperplasia,smooth muscle cells hypertrophy,fibroblasts and collagen fibers increase;thevolume of rat liver between liver cirrhosis group and control group is separately 9741±2715mm3 and 12898±3081 mm3 by CT scanning,the difference is statisticallysignificant;portal pressure between liver cirrhosis group and normal by manometry in ratsis 7.6±2.6mmHg and 12.9±3.7 mmHg respectively,difference between the two groupswas significant.
2.IGF-1 protein expression of two groups of liver tissue by immunohistochemicaldetection is 0.40±0.13 and 0.68±0.19,and the difference has statistical significance;IGF-1 mRNA of two groups of liver is 3.95±2.26 and 6.12±3.14 By RT-Real Time-PCRDetection,and the difference has statistical significance;serum IGF protein is 687±137ng/ ml and 919±183 ng/ ml Measured by ELISA,and the difference has statisticalsignificance;there is a negative correlation between liver cells IGF-1 concentrations orserum IGF-1 concentration as well as liver cells IGF-1 mRNA concentration and portalvein pressure By the linear analysis.
3.IGF-1 protein content caused different activity of gene promoter by -10 nucleotide polymorphism are 0.44±0.13 (AI) and 0.34±0.10 (AI) by sequence-specific primer PCRand asymmetric PCR and gene chip technology of liver cirrhosis in rats of liver cirrhosis,the difference has statistical significance;portal vein pressure were 13.0±3.5 (mmHg)and 9.6±2.6 (mmHg) caused by -35 nucleotide polymorphism,the difference between thetwo groups has statistical significance
CONCLUTIONS
1.It is a stable model similarly to human natural course of disease established by CCL4which characterized with vasculopathy in portal hypertension;it is an ideal model forstudying portal portal hypertension which has a significant change of vein hemodynamics.
2.The level of IGF-1 protein and gene transcription continues to drop according todeterioration of liver cirrhosis in rat model with cirrhotic portal hypertension.IGF-1 is aprotective factor in cirrhotic portal hypertension.
3.Variation of IGF-1 gene promoter region on -10,-35 base locus can lead to activitychanges of IGF-1 gene promoter,which affect gene expression changes of IGF-1,therebyaffect the vasculopathy in portal hypertension.Polymorphism of IGF-1 gene promoterleads to individual reaction in course of cirrhotic portal hypertension.
引文
[1]田德安，梁扩寰．门静脉高压症的病因与分类，门静脉高压症[M]．梁扩寰，李绍白主编．北京：人民军医出版社，第一版，1999．17～22．
[2]梁扩寰，黄自平．门静脉高压形成机制，门静脉高压症[M]．梁扩寰，李绍白主编．北京：人民军医出版社，第一版，1999．117～119．
[3]张顺财，石碧坚，王伟岸主编．慢性肝病[M]．北京：科学技术文献出版社，第一版，2005．269～272．
[4]李涛，杨镇．门脉高压性血管病变研究进展．世界华人消化杂志，2005(13)1：25．
[5]邹卫龙．门静脉高压性血管病变．医师进修杂志，2004(27)4：25-27．
[6]施宝民，杨镇，王秀艳等．血管内皮生长因子D基因转移对胆汁性肝硬变大鼠肝纤维化和门静脉压力的影响．中华实验外科杂志，2006，23(3)：33-35．
[7]艾建华，杨镇．热休克蛋白90在门静脉高压大鼠肠系膜血管中的表达．中华实验外科杂志，2005，22(2)：30-32．
[8]曾金华，杨镇，徐均．门静脉高压症患者脾静脉平滑肌细胞gax mRNA的表达．中华实验外科杂志，2007，24(1)：21-23．．
[9]Elena C,Clinzia C,Bsc CE,et al.Insulin-like growth factor-1 as a vascular protective factor.Circulation.2004;110(15):2260-2265.
[10]Kaplan RC,Stricker HD,Rohan TE,et al.Insulin -like growth factors and coronary heart diseases.Cardiol Rev.2005;13(1):35-39.
[11]Colao A,Spiezia S,Disomma C,et al.Circulating insulin -like growth factor-1 levels are correlated with the atherosclerotic profile in healthy subjects independently of age.J Endocrinol Invest.2005;28(5):440-8.
[12]Sesmilo G,Biller BM,Levadot J,et al.Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with hormone deficiency.A randomized,controlled Clinical Trial.Ann Intern Med.2000;133(2):111—122.
[13]Morali G,Shitrit AB,EranM,et al.Expression of insulin-like growth factor-Ⅰand insulin-like growth factor binding proteins during thioacetamide-induced liver cirrhosis in rats[J]. Growth Horm IGF Res, 2005,15 (5): 313-323.
[14]Sanz S, Pucilowska JB, Liu S, et al. Expression of insulin - like growth factor I by activated hepatic stellate cells reduces fibro genesis and enhances regeneration after liver injury[J]. Gut, 2005, 54 (1): 134-141.
[1]杨镇，裘法组，王家华．家兔血吸虫模型的建立及其特点．中华实验外科杂志，1993，10(4)：145-146．
[2]Martin J.Intrasplenic hepaticocellular transplantation as a hepatic support measure incirrhotic dogs preliminary results[J].Transplant Proc,1987,19(5):3930.
[3]Mclean E,Mclean AEM,Sutton PM.Instant cirrhosis:An improved method for producing cirrhosis in rats by simultaneous administration of carbon tetrachloride and phenobarbiton[J].Br J Exp Pathol,1996,50(3):502-510.
[4]Proctcr E,Chatamra.High yield micronodular cirrhosis in the rat[J].Gastroenterology,1982,83(5):1183-1190.
[5]Mulen KD,Mropi MD,Mocollough AJ.Problems with animal models of chronic liver disease:suggestions for improvement in standardization[J].Hepatology,1989,9:500-503.
[6]Tamayo RP.Is cirrhosis of the liver experimentally produced by CC14 an adequate model of human cirrhosis[J]? Hepatology,1983,3:112-120.
[7]Chae HB,Jang LC,Par SM,et al.An experimental model of hepatic fibrosis inducedby alcohol and CC14:can the lipopolysacchafide prevent liver injury induced by alcoholand CC14[J]? Taehan Kan Hakhoe Chi,2002,8:173-178.
[8]Sherlock S.Progress report,heptic reaction to drugs[J].Cut,1999,20(4):634-642.
[9]Cameron GR,Karunaratne WAE.Carbon tetrachloride cirrhosis in liver regeneration[J].J Pathol B acterial,1986,42(1):125.
[10]吕明德，黄洁夫．腹腔注射四氯化碳配合营养控制制备犬肝硬化模型[J]．中华实验外科杂志，1993，10(2)：58-61．
[11]马学惠．肝纤维化动物模型的制作方法[J]．中华肝脏病杂志，1996，4(1)：58-61．
[12]Runyon BA,Sugano S,Kanel G,et al.A rodent model of cirrhosis,ascite and bacterial peritonitis[J].Gastroenterology,1997,100(3):489-493.
[13]Tsukarnoto H,Reidelbermer RD,Frech SW,et al.Longterm cannulation in t he rat[J].Am J Pysiol,1994,247(4):595-599.
[14]Mori T,Sawa Y.Defenestration of the sinusoidal cell in a rat model of cirrhosis[J].Hepatology,1993,17(5):891-896.
[15]Cutrin C,Menino MJ,Perez-Becorra E,et al.Lactacidaem ia and perivenular fibrosis in an experimental model of cirrhosis in rat s carbon tetrarch loride and ethanol[J].Med Sci Res,1992,20:587-588.
[16]Chatam ra K,Proctor E.Phenobarbitone-induced enlargement of the liver in the rat:its relationship to carbon tetrachloride-induced cirrhosis[J].Br J Exp Path,1981,62:283-288.
[17]韩德五，马学惠，赵元昌．肝硬化动物模型的研究[J]．山西医药杂志，1989，4(1)：41-44．
[18]Friedman SL.The cellular basis of hepatic fibrosis.Mechanisms and treatmentstrategies.N Eng J Med,1993,328:1828-1835.
[19]Rocky DC.Vocative agents in intrahepatic portal hypertension and fibro-genesis:implications for therapy.Gastroenterology.2000,118(6):1261-1265.
[20]施斌．门脉高压症形成中门脉系统生物力学特性的实验研究[D]．上海，上海第二军医大学，20030401．
[21]杨镇，任大宏，李大鹏，等．门脉高压患者内脏血管壁的组织病理学改变[J]．同济医科大学学报，2000，29：34～36．
[22]张欣，王天才，唐望先，等．门脉高压患者及动物模型脾脏及脾静脉病理损伤研究[J]．同济医科大学学报，2000，29：507～510．
[23]李席如，何泽生，吴余生，等．门脉高压患者脾动静脉结构成分的变化[J]．华人消化杂志，1998，6：760～761．
[24]雷平，王芳元，高卉．爱脉朗预防大鼠肝硬化门脉高压症的实验研究[J]．咸宁医学院学报，2002，16(2)：1～3．
[25]Yasuda M,Shimizu L,Shiba M,et al.Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats[J].Hepatology,1999,29:719～727.
[1]Shimizu I,Mizobuchi Y,YasudaM,et al.Inhibitory effect of oes-tradiol on activation of rat hepatic stellate cells in vivo and in vitro[J].Gut,1999,44(1):127-136.国外医学·消化系疾病分册．
[2]ElsammakMY,Amin GM,Khalil GM,et al.Possible contribution of serum activin A andIGF-1 in the development of hepatocellularcarcinoma in Egyp tian patients suffering fromcombined hepatitis C virus infection and hepatic schistosomiasis[J].Clin Biochem,2006,39(6):623-629.
[3]Morali G,Shitrit AB,EranM,et al.Expression of insulin-like growth factor-Ⅰ and insulin-like growth factor binding p roteinsduring thioacetamide-induced liver cirrhosis in rats[J].Growth Horm IGF Res,2005,15(5):313-323.
[4]Sanz S,Pucilowska JB,Liu S,et al.Exp ression of insulin-like growth factor Ⅰ by activated hepatic stellate cells reduces fibro genesis and enhances regeneration after liver injury[J].Gut,2005,54(1):134-141.
[5]Garcia-Fem(?)ndezM,Castilla-Cort(?)zar I,Diaz-SanchezM,et al.Antioxidant effectsof insulin-like growth factor-Ⅰ(IGF-Ⅰ)in rats with advanced liver cirrhosis[J].BMC Gastroenterol,2005,3:527.
[6]Assy N,Pruzansky Y,Gaitini D,et al.Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction.J Hepatol.2008 Jul;49(1):34-42.
[7]Smith JC,Lane HA,Lewis J,et al.Endothelial function and coagulant factors in growth hormone treatrdhypopituitary adults receiving desmopressin.J Clin Endocrinol Metab.2003;88(5):2152-2156.
[8]Conchillo M,Prieto J,Quiroga J.Insulin-like growth factor Ⅰ(IGF-Ⅰ) and liver cirrhosis.Rev Esp Enferm Dig,2007 Mar;99(3):156-64.
[9]Sesmilo G,Biller BM,Levadot J,et al.Effects of growth hormone administration on inflammatory and other cardiovascular risk makers in men with hormone deficiency.A randomized controlled clinical trial.Ann Intern Med.2000;133(2):111—122.
[10] Laura A,Colangelo,Liu K,et al. Insulin -like growth factor-1, Insulin -like growth factor binding protein-3 and cardiovascular disease risk factors in young black men and white men .Am J Epidemiol. 2004; 160(8):750-757.
[11] Streicher R,Kotzka Z,Muller WD,et al. STREBP-1 mediates activation of the low density lipoprotein receptor promoter by insulin and insulin like growth factor-1 J Biol Chem. 1996; 271(12):7128-7133.
[12] Froesch ER, Zonobi PD,Hussain M. Metabolic and therapeutic effects of insulin-like growth factor-LHorm Res. 1994;42(1-2):66-71.
[13] Tan CB.Shin WM, Janus ED, et al. LDL subtraction in acromegaly: relation togrowth hormone and insulin -like growth factor-1.Atherosclerosis. 1997; 129(1):59-65.
[14] Kajstura 3,Fioradaliso F,Andreoli AM,et al. IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II -mediated oxidative stress.Diabetes. 2001;50(6):1414-1424.
[15] Higashi Y,Peng T,Du J,et al. A redox-sensitive pathway mediates oxidized L:DL-induced down regulaion of insulin -like growth factor-1 receptor.J Lipid Res.2005;46(6):1266-1277.
[16] Li YX,Higashi Y ,Itabe H,et al. Insulin -like growth factor-1 receptor activation inhibits oxidized LDL-induced cytochrome C release and apoptosis via the phosphatidylinositol 3-kinase/ Akt signaling pathway.ArteriosclerThromb Vasc Biol. 2003;23(12):2178-2184.
[17] Laura A,Colangelo,Liu K,et al. Insulin -like growth factor-1, Insulin -like growth factor binding protein-3 and cardiovascular disease risk factors in yovung black men and white men .Am J Epidemiol. 2004;160(8):750-757.
[18] Colao A,Spiezia S,Disomma C,et al. Circulating insulin -like growth factor-1 levels are correlated with the atherosclerotic profile in healthy subjects independently of age .Endocrinol Invest .2005;28(5):440-448.
[19] Sandhu MS, Heald AH,Gibson JM,et al. Circulating concentrations of insulin-like growth factor-land development of glucose intolerance:a prospective observational study.Lancet.2002;359(9319):1740-1745.
[20] Ciaraldi TP,Carter L,Rehman N,et al. Insulin and insulin -like growth factor-1 action in human skeletal muscle :preferential effects of insulin -like growth factor-lin type 2 diabetic subjects.Metabolism. 2002;51(9):1171-1179.
[21] Delafontaine P. Insulin-like growth factor-1 and its binding proteins in the cardiovascular system .Cardiovasc Res. 1995; 30(6):825-834.
[22] Conti E,Andreotti F,Sestito A,et al. Reduced levels of insulin-like growth factor-1 in patients with angia pectoris ,positive exercise stress test ,and angiographically normal epicardial coronary arteries .Am J Cardiol. 2002; 89(18): 973-975.
[23] Oltman CL, Kane NL, Gutterman DD, et al. Mechanism of coronary vasodilation to insulin and insulin-like growth factor-1 is dependent on vessel size .Am J Physiol Endocrinol Metab. 2000; 279(1):E 176-E 181.
[24] Twickler MT, Cramer MJ, Koppeschaar HP.et al. Un ravelng reaven's syndrome x:serum insulin-like growth factor-1 and cardiovascular disease.Circulation. 2003; 107(20):e190-e192.
[25] Galderisi M ,Caso P ,Cicala S ,et al. Positive association between circulating free insulin -like growth factor-1 levels and coronary flow reserve in arterial system hypertension.Am J Hypertens. 2002;15(9):766-772.
[26] Dimmeler S, Zeiher AM. Exercise and cardiovascular health: get active to "Aktivate" your endothelial nitric oxide synthase .Circulation. 2003;107(25):3118- 3120.
[27] Bayes-Genis A, Conover CA, Schwartz RS .The insulin -like growth factor axis:a review of atherosclerosis and restenosis.Cir Res. 2002;86(2):125-130.
[28] Patel VA,Zhang Q J,Siddle K,et al .Defect in insulin -like growth factor-1 survival mechanism in atherosclerotic plaque-derived vascular muscle cells is mediated reduced surface binding and signaling.Cir Res. 2001; 88 (9): 895-899.
(1).Auer J,Weber T,Berent R,et al.Genetic polymorphisms in cytokine and adhesion molecule genes in coronary artery disease.Am J Pharmacogenomics.2003;3(5):317-25.
(2).Luft FC.Present status of genetic mechanisms in hypertension.Med ClinNorth Am.2004;88(1):1-18.
(3)．李靖，潘玉春，李亦学，等。人类基因组单核营酸多态性和单体型的分析及应用。遗传学报，2005，32(8)：879-8890。
(4).Doherty TM,Fitzpatrick LA,Shaheen A,et al.Genetic determinants of arterial calcification associated with atherosclerosis.Clin Proc.2004;79:197-210.
(5).Hofler H,Specht K,Becker KF.Molecular analysis of gene expression in tumor pathology.Adv Exp Med Biol.2003;532:19-26.
(6).Mooser V,Waterworth DM,Isenhour T,et al.Cardiovascular pharmacogenetics in the SNP era.J Thromb Haemost.2003;1:1398-1402.
(7).Bataller R,North KE,Brenner DA.Genetic polymorphisms and the progression of liver fibrosis:a critical appraisal.Hepatology.2003;37:493—503.
(8).Hirayama K.Genetic factors associated with development of cerebral malaria and fibrotic schistosomiasis.Korean J Parasitol.2002;40:165—72.
(9).Auer J,Weber T,Berent R,et al.Genetic polymorphisms in cytokine and adhesion molecule genes in coronary artery disease.Am J Pharmacogenomics.2003;3(5):317-25.
(10).Luft FC.Present status of genetic mechanisms in hypertension.Med Clin North Am.2004;88(1):1—18.
(11) Schayek H,Haugk K,Sun S,et al.Tumor suppressor BRCA1 is expressed in Prostate cancer and controls insulin-like growth factor Ⅰ receptor(IGF-IR) gene transcription in an androgen receptor-dependent manner.Clin Cancer Res.2009 Mar 1;15(5):1558-65
(12) Meyer S,Schaefer S,Ivan D,et al._Growth hormone dose in growth hormone-deficient adults is not associated with IGF-1 gene polymorphisms.Pharmacogenomics.2009 Feb;10(2):293-302.
(13) Stratikopoulos E, Szabolcs M, Dragatsis I, The hormonal action of IGF1 in postnatal mouse growth.. Proc Natl Acad Sci USA. 2008 Dec 9;105(49): 19378-83.
(14) Economou MA, Wu J, Vasilcanu D, et al. Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor. Acta Ophthalmol. 2008 Nov;86 Thesis 4:42-9.
(15) Semenova E, Koegel H, Hasse S, et al. Overexpression of mIGF-1 in keratinocytes improves wound healing and accelerates hair follicle formation and cycling in mice. Am J Pathol. 2008 Nov; 173 (5): 1295-310.
(16) Xie L, Gong YY, Lian SG, et al. Absence of association between SNPs in the promoter region of the insulin-like growth factor 1 (IGF-1) gene and longevity in the Han Chinese population. Exp Gerontol. 2008 Oct;43(10):962-5.
[1]Rajaram S,Baylink D J,Mohan S.Insulin-like growth factor-binding proteins in serum and other biological fluids:regulation and functions.Endocr Rev,1997,18:801-831.
[2]Woods KA,Camacho-Hubner C,Savage MO,et al.Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor Ⅰ gene.N Engl J Med,1996,335:1363-1367.
[3]Hirschberg R,Adler S.Insulin-like growth factor system and the kidney:physiology,pathophysiology and therapeutic implication.Am J Kindey Dis,1998,31:901-919.
[4]Estivariz CF,Zieyler TR.Nutrition and the insulin-like growth factor system.Endocrine,1997,7:65-71.
[5]Dunger DB,Cheetham TD.Growth hormone insulin-like growth factor Ⅰ axis in insulin-dependent diabetes mellitus.Horm Res,1996,46:2-6.
[6]Kurland ES,Rosen C J,Cosman F,et al.Insulin-like growth factor-Ⅰ in men with idiopathic osteoporosis.J Clin Endocrinol Metab,1997,82:2799-2805.
[7]Jehle PM,Jehle DR,Mohan S,et al.Serum levels of insulin-like growth factor system components and relationship to bone metabolism in type Ⅰ and type Ⅱ diabetes mellitus patients.J Endocrinol,1998,159:297-306.
[8]Baxter RC.The role of insulin-like growth factors and their binding protein in tumor hypoglycemia.Horm Res,1996,46:195-201.
[9]Laron Z,Anin S,Klipper-Aurbach Y,et al.Effects of insulin-like growth factors on linear growth,head circumference,and body fat in patients with Laron-type dwarfism.Lancet,1992,339:1258-1261.
[10]Likitmaskul S,Watcharasindhu s,Angsusingha K,et al.IGF-Ⅰ generation test in non-growth hormone deficient short children.Horm Res,1998,49:52.
[11]Cheetham LD,Holly JMP,Clayton K,et al.The effects of repeated daily recombinant human insulin-like growth factor Ⅰ administration in adolescents with type 1 diabetes.Diabetic Med,1995,12:885-862.
[12]Anton-Lewis U,Madigan T,Burguera B,et al.Tteatment of insulin-resistance diabetic ketoacidosis with insulin-like growth factor Ⅰ in an adolescent with insulin-dependent diabetes.N Engl J Med,1992,327:853-857.
[13]Zenobi PD,Jacggi-Groisman SE,Riesen WF,et al.Insulin-like growth factor Ⅰ improves glucose and lipid metabolism in type Ⅰ diabetes mellitus.J Clin Invest,1992,90:2234-2241.
[14]Moses AC,Young SCJ,Morrow LA,et al.Recombinant human insulin-like growth factor Ⅰ increases insulin sensitivity and improves glycemic control in type Ⅱ diabetes.Diabetes,1996,45:91-100.
[15]Schoenle EJ,Zenobi PD,Torresani T,et al.Recombinant human insulin-like growth factor Ⅰ(IGF-Ⅰ) reduces hyperglycemia in patients with extreme insulin resistance.Diabetologia,1991,34:675-679.
[16]Moses AC,Morrow LA,O'Brien M,et al.Insulin-like growth factor Ⅰ(rhIGF-Ⅰ) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus.Diabetes Res Clin Pract,1995,28:S185-195.
[17]Crowne EC,Samra JS,Cheetham T,et al.Recombinent human insulin-like growth factor-Ⅰ abolishes changes in insulin requirements consequent upon growth hormone pulsatility in young adults with type Ⅰ diabetes mellitus.Metablism,1998,47:31-38.
[18]Ishii DN.Implication of insulin-like growth factors in the pathogenesis of diabetic neuropathy.Brain Res Revi,1995,20:47-67.
[19]Torresaleman I,Barrios V.Berciano J.The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis.Neurology,1998,50:772-776.
[20]Roith DL.Insulin-like growth factors.N Engl J Med,1997,336:633-640.
[21]Acerini CL,Patton CM,Savage MO,et al.Randomised placebo-controlled trial of human recombinant insulin-like growth factor-Ⅰ plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus.Lancet,1997,350:1199-1204.
[22] Sakurai T, Ueda T, Kawai M, et al. Protective effects of insulin-like growth factor-I on the decrease in myogenic differentiation by ionizing radiation.. Int J Radiat Biol. 2009 Feb;85(2):153-8.
[23] Wang X, Lu L, Li Y, Li M, et al. Molecular and functional characterization of two distinct IGF binding protein-6 genes in zebrafish. . Am J Physiol Regul Integr Comp Physiol. 2009 Mar 11. [Epub ahead of print]
[24] Alajajian BB, Fletcher L, Isgor E, et al. IGF-I regulated phosphorylation and translocation of PDK-1 in neurons. Neuroreport. 2009 Mar 7. [Epub ahead of print]
[25] Rikhof B, van Doorn J, Suurmeijer AJ, et al. Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour. Ann Oncol. 2009 Mar 10. [Epub ahead of print]
[26] Gualco E, Wang JY, Del Valle L, et al. IGF-IR in neuroprotection and brain tumors. Front Biosci. 2009 Jan l;14:352-75.
[27] Adamis D, Lunn M, Martin FC, et al. Cytokines and IGF-I in delirious and non-delirious acutely Ill older medical inpatients. Age Ageing. 2009 Mar 5.
[28]Motobayashi Y, Izawa-Ishizawa Y, Ishizawa K, et al. Adiponectin inhibits insulin-like growth factor-1-induced cell migration by the suppression of extracellular signal-regulated kinase 1/2 activation, but not Akt in vascular smooth muscle cells. Hypertens Res. 2009 Mar;32(3):188-93.
[29] Davidson S, Prokonov D, Taler M, et al. Effect of exposure to selective serotonin reuptake inhibitors in utero on fetal growth: potential role for the IGF-I and HPA axes. Pediatr Res. 2009 Feb;65(2):236-41.
[30] Deblaquiere G, May F, Westley B. Increased expression of both insulin receptor substrates 1 and 2 confers increased sensitivity to IGF-1 stimulated cell migration. Endocr Relat Cancer. 2009 Mar 4.
[31] Sirotkin AV, Rafay J, Kotwica J, et al. Role of ghrelin in regulating rabbit ovarian function and the response to LH and IGF-Ⅰ.Domest Anim Endocrinol.2009 Jan 22.
[32]Dhali A,Anchamparuthy VM,Butler SP,et al.In vitro development of bovine embryos cultured with stem cell factor or insulin-like growth factor-Ⅰ following IVF with semen of two bulls having different field fertility.Anim Reprod Sci.2009 Feb 11.[Epub ahead of print]
[33]Leibowitz BJ,Cohick WS.Endogenous IGFBP-3 is required for both growth factor-stimulated cell proliferation and cytokine-induced apoptosis in mammary epithelial cells.J Cell Physiol.2009 Mar 3.[Epub ahead of print]
[34]Kim B,Feldman EL.Insulin receptor substrate(IRS)-2,not IRS-1,protects human neuroblastoma cells against apoptosis.Apoptosis.2009 Mar 4.[Epub ahead of print]
[35]Brown J,Jones EY,Forbes BE.Chapter 25 Interactions of IGF-Ⅱ with the IGF2R/Cation-Independent Mannose-6-Phosphate Receptor Mechanism and Biological Outcomes.Vitam Horm.2009;80:699-719.
[36]Wheeler CA,Jafarzadeh SR,Rocke DM,et al.IGF-1 does not moderate the time-dependent transcriptional pattems of key homeostatic genes induced by sustained compression of bovine cartilage.Osteoarthritis Cartilage.2009 Feb 15.[Epub ahead of print]
[37]Kwon J,Stephan S,Mukhopadhyay A,et al.Insulin receptor substrate-2 mediated insulin-like growth factor-Ⅰ receptor overexpression in pancreatic adenocarcinoma through protein kinase Cdelta.Cancer Res.2009 Feb 15;69(4):1350-7.
[38]Kojima S,Inahara M,Suzuki H,et al.Implications of insulin-like growth factor-Ⅰ for prostate cancer therapies.Int J Urol.2009 Feb;16(2):161-7.
[39]Hu C,Wu Y,Wan Y,et al.Introduction of hIGF-1 gene into bone marrow stromal cells and its effects on the cell's biological behaviors.Cell Transplant.2008;17(9):1067-81.
[40]Okamoto N,Yamanaka N,Satake H,et al.An ecdysteroid-inducible insulin-like growth factor-like peptide regulates adult development of the silkmoth Bombyx mori.FEBS J.2009 Mar;276(5):1221-32.
[41]Klinakis A,Szabolcs M,Chen G,et al.Igflr as a therapeutic target in a mouse model of basal-like breast cancer.Proc Natl Acad Sci U S A.2009 Feb 17;106(7):2359-64.
[42]Araki W,Kume H,Oda A,et al.IGF-1 promotes beta-amyloid production by a secretase-independent mechanism.Biochem Biophys Res Commun.2009 Feb 27;380(1):111-4.
[43]Descamps G,Gomez-Bougie P,Venot C,et al.A humanised anti-IGF-1R monoclonal antibody(AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45.Br J Cancer.2009 Jan 27;100(2):366-9.
[44]Yin S,Zhou X,Peng T,et al.Expression and clinical significance of insulin like growth factor-1 protein in nasopharyngeal carcinoma.Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.2008 Oct;22(19):874-7.
[45]Broughton S,Partridge L.Insulin/IGF-like signalling,the central nervous system and aging.Biochem J.2009 Feb 15;418(1):1-12.
[46]Rikhof B,de Jong S,Suurmeijer AJ,et al.The insulin-like growth factor system and sarcomas.J Pathol.2009 Mar;217(4):469-82.
[47]Sivakumar R,Koga H,Selvendiran K,et al.Autocrine loop for IGF-Ⅰ receptor signaling in SLUG-mediated epithelial-mesenchymal transition.Int J Oncol.2009 Feb;34(2):329-38.
[48]Franz CK,Federici T,Yang J,et al.Intraspinal cord delivery of IGF-Ⅰ mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS.Neurobiol Dis.2009 Mar;33(3):473-81.
[50]de Ostrovich KK,Lambertz I,et al.Paracrine overexpression of insulin-like growth factor-1 enhances mammary tumorigenesis in vivo.Am J Pathol.2008 Sep;173(3):824-34.
[51]Eleswarapu S,Gu Z,Jiang H.Growth hormone regulation of insulin-like growth factor-Ⅰ gene expression may be mediated by multiple distal signal transducer and activator of transcription 5 binding sites.Endocrinology.2008 May;149(5):2230-40.
[2]梁扩寰，黄自平．门静脉高压形成机制，门静脉高压症[M]．梁扩寰，李绍白主编．北京：人民军医出版社，第一版，1999．117～119．
[3]张顺财，石碧坚，王伟岸主编．慢性肝病[M]．北京：科学技术文献出版社，第一版，2005．269～272．
[4]李涛，杨镇．门脉高压性血管病变研究进展．世界华人消化杂志，2005(13)1：25．
[5]邹卫龙．门静脉高压性血管病变．医师进修杂志，2004(27)4：25-27．
[6]施宝民，杨镇，王秀艳等．血管内皮生长因子D基因转移对胆汁性肝硬变大鼠肝纤维化和门静脉压力的影响．中华实验外科杂志，2006，23(3)：33-35．
[7]艾建华，杨镇．热休克蛋白90在门静脉高压大鼠肠系膜血管中的表达．中华实验外科杂志，2005，22(2)：30-32．
[8]曾金华，杨镇，徐均．门静脉高压症患者脾静脉平滑肌细胞gax mRNA的表达．中华实验外科杂志，2007，24(1)：21-23．．
[9]Elena C,Clinzia C,Bsc CE,et al.Insulin-like growth factor-1 as a vascular protective factor.Circulation.2004;110(15):2260-2265.
[10]Kaplan RC,Stricker HD,Rohan TE,et al.Insulin -like growth factors and coronary heart diseases.Cardiol Rev.2005;13(1):35-39.
[11]Colao A,Spiezia S,Disomma C,et al.Circulating insulin -like growth factor-1 levels are correlated with the atherosclerotic profile in healthy subjects independently of age.J Endocrinol Invest.2005;28(5):440-8.
[12]Sesmilo G,Biller BM,Levadot J,et al.Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with hormone deficiency.A randomized,controlled Clinical Trial.Ann Intern Med.2000;133(2):111—122.
[13]Morali G,Shitrit AB,EranM,et al.Expression of insulin-like growth factor-Ⅰand insulin-like growth factor binding proteins during thioacetamide-induced liver cirrhosis in rats[J]. Growth Horm IGF Res, 2005,15 (5): 313-323.
[14]Sanz S, Pucilowska JB, Liu S, et al. Expression of insulin - like growth factor I by activated hepatic stellate cells reduces fibro genesis and enhances regeneration after liver injury[J]. Gut, 2005, 54 (1): 134-141.
[1]杨镇，裘法组，王家华．家兔血吸虫模型的建立及其特点．中华实验外科杂志，1993，10(4)：145-146．
[2]Martin J.Intrasplenic hepaticocellular transplantation as a hepatic support measure incirrhotic dogs preliminary results[J].Transplant Proc,1987,19(5):3930.
[3]Mclean E,Mclean AEM,Sutton PM.Instant cirrhosis:An improved method for producing cirrhosis in rats by simultaneous administration of carbon tetrachloride and phenobarbiton[J].Br J Exp Pathol,1996,50(3):502-510.
[4]Proctcr E,Chatamra.High yield micronodular cirrhosis in the rat[J].Gastroenterology,1982,83(5):1183-1190.
[5]Mulen KD,Mropi MD,Mocollough AJ.Problems with animal models of chronic liver disease:suggestions for improvement in standardization[J].Hepatology,1989,9:500-503.
[6]Tamayo RP.Is cirrhosis of the liver experimentally produced by CC14 an adequate model of human cirrhosis[J]? Hepatology,1983,3:112-120.
[7]Chae HB,Jang LC,Par SM,et al.An experimental model of hepatic fibrosis inducedby alcohol and CC14:can the lipopolysacchafide prevent liver injury induced by alcoholand CC14[J]? Taehan Kan Hakhoe Chi,2002,8:173-178.
[8]Sherlock S.Progress report,heptic reaction to drugs[J].Cut,1999,20(4):634-642.
[9]Cameron GR,Karunaratne WAE.Carbon tetrachloride cirrhosis in liver regeneration[J].J Pathol B acterial,1986,42(1):125.
[10]吕明德，黄洁夫．腹腔注射四氯化碳配合营养控制制备犬肝硬化模型[J]．中华实验外科杂志，1993，10(2)：58-61．
[11]马学惠．肝纤维化动物模型的制作方法[J]．中华肝脏病杂志，1996，4(1)：58-61．
[12]Runyon BA,Sugano S,Kanel G,et al.A rodent model of cirrhosis,ascite and bacterial peritonitis[J].Gastroenterology,1997,100(3):489-493.
[13]Tsukarnoto H,Reidelbermer RD,Frech SW,et al.Longterm cannulation in t he rat[J].Am J Pysiol,1994,247(4):595-599.
[14]Mori T,Sawa Y.Defenestration of the sinusoidal cell in a rat model of cirrhosis[J].Hepatology,1993,17(5):891-896.
[15]Cutrin C,Menino MJ,Perez-Becorra E,et al.Lactacidaem ia and perivenular fibrosis in an experimental model of cirrhosis in rat s carbon tetrarch loride and ethanol[J].Med Sci Res,1992,20:587-588.
[16]Chatam ra K,Proctor E.Phenobarbitone-induced enlargement of the liver in the rat:its relationship to carbon tetrachloride-induced cirrhosis[J].Br J Exp Path,1981,62:283-288.
[17]韩德五，马学惠，赵元昌．肝硬化动物模型的研究[J]．山西医药杂志，1989，4(1)：41-44．
[18]Friedman SL.The cellular basis of hepatic fibrosis.Mechanisms and treatmentstrategies.N Eng J Med,1993,328:1828-1835.
[19]Rocky DC.Vocative agents in intrahepatic portal hypertension and fibro-genesis:implications for therapy.Gastroenterology.2000,118(6):1261-1265.
[20]施斌．门脉高压症形成中门脉系统生物力学特性的实验研究[D]．上海，上海第二军医大学，20030401．
[21]杨镇，任大宏，李大鹏，等．门脉高压患者内脏血管壁的组织病理学改变[J]．同济医科大学学报，2000，29：34～36．
[22]张欣，王天才，唐望先，等．门脉高压患者及动物模型脾脏及脾静脉病理损伤研究[J]．同济医科大学学报，2000，29：507～510．
[23]李席如，何泽生，吴余生，等．门脉高压患者脾动静脉结构成分的变化[J]．华人消化杂志，1998，6：760～761．
[24]雷平，王芳元，高卉．爱脉朗预防大鼠肝硬化门脉高压症的实验研究[J]．咸宁医学院学报，2002，16(2)：1～3．
[25]Yasuda M,Shimizu L,Shiba M,et al.Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats[J].Hepatology,1999,29:719～727.
[1]Shimizu I,Mizobuchi Y,YasudaM,et al.Inhibitory effect of oes-tradiol on activation of rat hepatic stellate cells in vivo and in vitro[J].Gut,1999,44(1):127-136.国外医学·消化系疾病分册．
[2]ElsammakMY,Amin GM,Khalil GM,et al.Possible contribution of serum activin A andIGF-1 in the development of hepatocellularcarcinoma in Egyp tian patients suffering fromcombined hepatitis C virus infection and hepatic schistosomiasis[J].Clin Biochem,2006,39(6):623-629.
[3]Morali G,Shitrit AB,EranM,et al.Expression of insulin-like growth factor-Ⅰ and insulin-like growth factor binding p roteinsduring thioacetamide-induced liver cirrhosis in rats[J].Growth Horm IGF Res,2005,15(5):313-323.
[4]Sanz S,Pucilowska JB,Liu S,et al.Exp ression of insulin-like growth factor Ⅰ by activated hepatic stellate cells reduces fibro genesis and enhances regeneration after liver injury[J].Gut,2005,54(1):134-141.
[5]Garcia-Fem(?)ndezM,Castilla-Cort(?)zar I,Diaz-SanchezM,et al.Antioxidant effectsof insulin-like growth factor-Ⅰ(IGF-Ⅰ)in rats with advanced liver cirrhosis[J].BMC Gastroenterol,2005,3:527.
[6]Assy N,Pruzansky Y,Gaitini D,et al.Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction.J Hepatol.2008 Jul;49(1):34-42.
[7]Smith JC,Lane HA,Lewis J,et al.Endothelial function and coagulant factors in growth hormone treatrdhypopituitary adults receiving desmopressin.J Clin Endocrinol Metab.2003;88(5):2152-2156.
[8]Conchillo M,Prieto J,Quiroga J.Insulin-like growth factor Ⅰ(IGF-Ⅰ) and liver cirrhosis.Rev Esp Enferm Dig,2007 Mar;99(3):156-64.
[9]Sesmilo G,Biller BM,Levadot J,et al.Effects of growth hormone administration on inflammatory and other cardiovascular risk makers in men with hormone deficiency.A randomized controlled clinical trial.Ann Intern Med.2000;133(2):111—122.
[10] Laura A,Colangelo,Liu K,et al. Insulin -like growth factor-1, Insulin -like growth factor binding protein-3 and cardiovascular disease risk factors in young black men and white men .Am J Epidemiol. 2004; 160(8):750-757.
[11] Streicher R,Kotzka Z,Muller WD,et al. STREBP-1 mediates activation of the low density lipoprotein receptor promoter by insulin and insulin like growth factor-1 J Biol Chem. 1996; 271(12):7128-7133.
[12] Froesch ER, Zonobi PD,Hussain M. Metabolic and therapeutic effects of insulin-like growth factor-LHorm Res. 1994;42(1-2):66-71.
[13] Tan CB.Shin WM, Janus ED, et al. LDL subtraction in acromegaly: relation togrowth hormone and insulin -like growth factor-1.Atherosclerosis. 1997; 129(1):59-65.
[14] Kajstura 3,Fioradaliso F,Andreoli AM,et al. IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II -mediated oxidative stress.Diabetes. 2001;50(6):1414-1424.
[15] Higashi Y,Peng T,Du J,et al. A redox-sensitive pathway mediates oxidized L:DL-induced down regulaion of insulin -like growth factor-1 receptor.J Lipid Res.2005;46(6):1266-1277.
[16] Li YX,Higashi Y ,Itabe H,et al. Insulin -like growth factor-1 receptor activation inhibits oxidized LDL-induced cytochrome C release and apoptosis via the phosphatidylinositol 3-kinase/ Akt signaling pathway.ArteriosclerThromb Vasc Biol. 2003;23(12):2178-2184.
[17] Laura A,Colangelo,Liu K,et al. Insulin -like growth factor-1, Insulin -like growth factor binding protein-3 and cardiovascular disease risk factors in yovung black men and white men .Am J Epidemiol. 2004;160(8):750-757.
[18] Colao A,Spiezia S,Disomma C,et al. Circulating insulin -like growth factor-1 levels are correlated with the atherosclerotic profile in healthy subjects independently of age .Endocrinol Invest .2005;28(5):440-448.
[19] Sandhu MS, Heald AH,Gibson JM,et al. Circulating concentrations of insulin-like growth factor-land development of glucose intolerance:a prospective observational study.Lancet.2002;359(9319):1740-1745.
[20] Ciaraldi TP,Carter L,Rehman N,et al. Insulin and insulin -like growth factor-1 action in human skeletal muscle :preferential effects of insulin -like growth factor-lin type 2 diabetic subjects.Metabolism. 2002;51(9):1171-1179.
[21] Delafontaine P. Insulin-like growth factor-1 and its binding proteins in the cardiovascular system .Cardiovasc Res. 1995; 30(6):825-834.
[22] Conti E,Andreotti F,Sestito A,et al. Reduced levels of insulin-like growth factor-1 in patients with angia pectoris ,positive exercise stress test ,and angiographically normal epicardial coronary arteries .Am J Cardiol. 2002; 89(18): 973-975.
[23] Oltman CL, Kane NL, Gutterman DD, et al. Mechanism of coronary vasodilation to insulin and insulin-like growth factor-1 is dependent on vessel size .Am J Physiol Endocrinol Metab. 2000; 279(1):E 176-E 181.
[24] Twickler MT, Cramer MJ, Koppeschaar HP.et al. Un ravelng reaven's syndrome x:serum insulin-like growth factor-1 and cardiovascular disease.Circulation. 2003; 107(20):e190-e192.
[25] Galderisi M ,Caso P ,Cicala S ,et al. Positive association between circulating free insulin -like growth factor-1 levels and coronary flow reserve in arterial system hypertension.Am J Hypertens. 2002;15(9):766-772.
[26] Dimmeler S, Zeiher AM. Exercise and cardiovascular health: get active to "Aktivate" your endothelial nitric oxide synthase .Circulation. 2003;107(25):3118- 3120.
[27] Bayes-Genis A, Conover CA, Schwartz RS .The insulin -like growth factor axis:a review of atherosclerosis and restenosis.Cir Res. 2002;86(2):125-130.
[28] Patel VA,Zhang Q J,Siddle K,et al .Defect in insulin -like growth factor-1 survival mechanism in atherosclerotic plaque-derived vascular muscle cells is mediated reduced surface binding and signaling.Cir Res. 2001; 88 (9): 895-899.
(1).Auer J,Weber T,Berent R,et al.Genetic polymorphisms in cytokine and adhesion molecule genes in coronary artery disease.Am J Pharmacogenomics.2003;3(5):317-25.
(2).Luft FC.Present status of genetic mechanisms in hypertension.Med ClinNorth Am.2004;88(1):1-18.
(3)．李靖，潘玉春，李亦学，等。人类基因组单核营酸多态性和单体型的分析及应用。遗传学报，2005，32(8)：879-8890。
(4).Doherty TM,Fitzpatrick LA,Shaheen A,et al.Genetic determinants of arterial calcification associated with atherosclerosis.Clin Proc.2004;79:197-210.
(5).Hofler H,Specht K,Becker KF.Molecular analysis of gene expression in tumor pathology.Adv Exp Med Biol.2003;532:19-26.
(6).Mooser V,Waterworth DM,Isenhour T,et al.Cardiovascular pharmacogenetics in the SNP era.J Thromb Haemost.2003;1:1398-1402.
(7).Bataller R,North KE,Brenner DA.Genetic polymorphisms and the progression of liver fibrosis:a critical appraisal.Hepatology.2003;37:493—503.
(8).Hirayama K.Genetic factors associated with development of cerebral malaria and fibrotic schistosomiasis.Korean J Parasitol.2002;40:165—72.
(9).Auer J,Weber T,Berent R,et al.Genetic polymorphisms in cytokine and adhesion molecule genes in coronary artery disease.Am J Pharmacogenomics.2003;3(5):317-25.
(10).Luft FC.Present status of genetic mechanisms in hypertension.Med Clin North Am.2004;88(1):1—18.
(11) Schayek H,Haugk K,Sun S,et al.Tumor suppressor BRCA1 is expressed in Prostate cancer and controls insulin-like growth factor Ⅰ receptor(IGF-IR) gene transcription in an androgen receptor-dependent manner.Clin Cancer Res.2009 Mar 1;15(5):1558-65
(12) Meyer S,Schaefer S,Ivan D,et al._Growth hormone dose in growth hormone-deficient adults is not associated with IGF-1 gene polymorphisms.Pharmacogenomics.2009 Feb;10(2):293-302.
(13) Stratikopoulos E, Szabolcs M, Dragatsis I, The hormonal action of IGF1 in postnatal mouse growth.. Proc Natl Acad Sci USA. 2008 Dec 9;105(49): 19378-83.
(14) Economou MA, Wu J, Vasilcanu D, et al. Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor. Acta Ophthalmol. 2008 Nov;86 Thesis 4:42-9.
(15) Semenova E, Koegel H, Hasse S, et al. Overexpression of mIGF-1 in keratinocytes improves wound healing and accelerates hair follicle formation and cycling in mice. Am J Pathol. 2008 Nov; 173 (5): 1295-310.
(16) Xie L, Gong YY, Lian SG, et al. Absence of association between SNPs in the promoter region of the insulin-like growth factor 1 (IGF-1) gene and longevity in the Han Chinese population. Exp Gerontol. 2008 Oct;43(10):962-5.
[1]Rajaram S,Baylink D J,Mohan S.Insulin-like growth factor-binding proteins in serum and other biological fluids:regulation and functions.Endocr Rev,1997,18:801-831.
[2]Woods KA,Camacho-Hubner C,Savage MO,et al.Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor Ⅰ gene.N Engl J Med,1996,335:1363-1367.
[3]Hirschberg R,Adler S.Insulin-like growth factor system and the kidney:physiology,pathophysiology and therapeutic implication.Am J Kindey Dis,1998,31:901-919.
[4]Estivariz CF,Zieyler TR.Nutrition and the insulin-like growth factor system.Endocrine,1997,7:65-71.
[5]Dunger DB,Cheetham TD.Growth hormone insulin-like growth factor Ⅰ axis in insulin-dependent diabetes mellitus.Horm Res,1996,46:2-6.
[6]Kurland ES,Rosen C J,Cosman F,et al.Insulin-like growth factor-Ⅰ in men with idiopathic osteoporosis.J Clin Endocrinol Metab,1997,82:2799-2805.
[7]Jehle PM,Jehle DR,Mohan S,et al.Serum levels of insulin-like growth factor system components and relationship to bone metabolism in type Ⅰ and type Ⅱ diabetes mellitus patients.J Endocrinol,1998,159:297-306.
[8]Baxter RC.The role of insulin-like growth factors and their binding protein in tumor hypoglycemia.Horm Res,1996,46:195-201.
[9]Laron Z,Anin S,Klipper-Aurbach Y,et al.Effects of insulin-like growth factors on linear growth,head circumference,and body fat in patients with Laron-type dwarfism.Lancet,1992,339:1258-1261.
[10]Likitmaskul S,Watcharasindhu s,Angsusingha K,et al.IGF-Ⅰ generation test in non-growth hormone deficient short children.Horm Res,1998,49:52.
[11]Cheetham LD,Holly JMP,Clayton K,et al.The effects of repeated daily recombinant human insulin-like growth factor Ⅰ administration in adolescents with type 1 diabetes.Diabetic Med,1995,12:885-862.
[12]Anton-Lewis U,Madigan T,Burguera B,et al.Tteatment of insulin-resistance diabetic ketoacidosis with insulin-like growth factor Ⅰ in an adolescent with insulin-dependent diabetes.N Engl J Med,1992,327:853-857.
[13]Zenobi PD,Jacggi-Groisman SE,Riesen WF,et al.Insulin-like growth factor Ⅰ improves glucose and lipid metabolism in type Ⅰ diabetes mellitus.J Clin Invest,1992,90:2234-2241.
[14]Moses AC,Young SCJ,Morrow LA,et al.Recombinant human insulin-like growth factor Ⅰ increases insulin sensitivity and improves glycemic control in type Ⅱ diabetes.Diabetes,1996,45:91-100.
[15]Schoenle EJ,Zenobi PD,Torresani T,et al.Recombinant human insulin-like growth factor Ⅰ(IGF-Ⅰ) reduces hyperglycemia in patients with extreme insulin resistance.Diabetologia,1991,34:675-679.
[16]Moses AC,Morrow LA,O'Brien M,et al.Insulin-like growth factor Ⅰ(rhIGF-Ⅰ) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus.Diabetes Res Clin Pract,1995,28:S185-195.
[17]Crowne EC,Samra JS,Cheetham T,et al.Recombinent human insulin-like growth factor-Ⅰ abolishes changes in insulin requirements consequent upon growth hormone pulsatility in young adults with type Ⅰ diabetes mellitus.Metablism,1998,47:31-38.
[18]Ishii DN.Implication of insulin-like growth factors in the pathogenesis of diabetic neuropathy.Brain Res Revi,1995,20:47-67.
[19]Torresaleman I,Barrios V.Berciano J.The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis.Neurology,1998,50:772-776.
[20]Roith DL.Insulin-like growth factors.N Engl J Med,1997,336:633-640.
[21]Acerini CL,Patton CM,Savage MO,et al.Randomised placebo-controlled trial of human recombinant insulin-like growth factor-Ⅰ plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus.Lancet,1997,350:1199-1204.
[22] Sakurai T, Ueda T, Kawai M, et al. Protective effects of insulin-like growth factor-I on the decrease in myogenic differentiation by ionizing radiation.. Int J Radiat Biol. 2009 Feb;85(2):153-8.
[23] Wang X, Lu L, Li Y, Li M, et al. Molecular and functional characterization of two distinct IGF binding protein-6 genes in zebrafish. . Am J Physiol Regul Integr Comp Physiol. 2009 Mar 11. [Epub ahead of print]
[24] Alajajian BB, Fletcher L, Isgor E, et al. IGF-I regulated phosphorylation and translocation of PDK-1 in neurons. Neuroreport. 2009 Mar 7. [Epub ahead of print]
[25] Rikhof B, van Doorn J, Suurmeijer AJ, et al. Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour. Ann Oncol. 2009 Mar 10. [Epub ahead of print]
[26] Gualco E, Wang JY, Del Valle L, et al. IGF-IR in neuroprotection and brain tumors. Front Biosci. 2009 Jan l;14:352-75.
[27] Adamis D, Lunn M, Martin FC, et al. Cytokines and IGF-I in delirious and non-delirious acutely Ill older medical inpatients. Age Ageing. 2009 Mar 5.
[28]Motobayashi Y, Izawa-Ishizawa Y, Ishizawa K, et al. Adiponectin inhibits insulin-like growth factor-1-induced cell migration by the suppression of extracellular signal-regulated kinase 1/2 activation, but not Akt in vascular smooth muscle cells. Hypertens Res. 2009 Mar;32(3):188-93.
[29] Davidson S, Prokonov D, Taler M, et al. Effect of exposure to selective serotonin reuptake inhibitors in utero on fetal growth: potential role for the IGF-I and HPA axes. Pediatr Res. 2009 Feb;65(2):236-41.
[30] Deblaquiere G, May F, Westley B. Increased expression of both insulin receptor substrates 1 and 2 confers increased sensitivity to IGF-1 stimulated cell migration. Endocr Relat Cancer. 2009 Mar 4.
[31] Sirotkin AV, Rafay J, Kotwica J, et al. Role of ghrelin in regulating rabbit ovarian function and the response to LH and IGF-Ⅰ.Domest Anim Endocrinol.2009 Jan 22.
[32]Dhali A,Anchamparuthy VM,Butler SP,et al.In vitro development of bovine embryos cultured with stem cell factor or insulin-like growth factor-Ⅰ following IVF with semen of two bulls having different field fertility.Anim Reprod Sci.2009 Feb 11.[Epub ahead of print]
[33]Leibowitz BJ,Cohick WS.Endogenous IGFBP-3 is required for both growth factor-stimulated cell proliferation and cytokine-induced apoptosis in mammary epithelial cells.J Cell Physiol.2009 Mar 3.[Epub ahead of print]
[34]Kim B,Feldman EL.Insulin receptor substrate(IRS)-2,not IRS-1,protects human neuroblastoma cells against apoptosis.Apoptosis.2009 Mar 4.[Epub ahead of print]
[35]Brown J,Jones EY,Forbes BE.Chapter 25 Interactions of IGF-Ⅱ with the IGF2R/Cation-Independent Mannose-6-Phosphate Receptor Mechanism and Biological Outcomes.Vitam Horm.2009;80:699-719.
[36]Wheeler CA,Jafarzadeh SR,Rocke DM,et al.IGF-1 does not moderate the time-dependent transcriptional pattems of key homeostatic genes induced by sustained compression of bovine cartilage.Osteoarthritis Cartilage.2009 Feb 15.[Epub ahead of print]
[37]Kwon J,Stephan S,Mukhopadhyay A,et al.Insulin receptor substrate-2 mediated insulin-like growth factor-Ⅰ receptor overexpression in pancreatic adenocarcinoma through protein kinase Cdelta.Cancer Res.2009 Feb 15;69(4):1350-7.
[38]Kojima S,Inahara M,Suzuki H,et al.Implications of insulin-like growth factor-Ⅰ for prostate cancer therapies.Int J Urol.2009 Feb;16(2):161-7.
[39]Hu C,Wu Y,Wan Y,et al.Introduction of hIGF-1 gene into bone marrow stromal cells and its effects on the cell's biological behaviors.Cell Transplant.2008;17(9):1067-81.
[40]Okamoto N,Yamanaka N,Satake H,et al.An ecdysteroid-inducible insulin-like growth factor-like peptide regulates adult development of the silkmoth Bombyx mori.FEBS J.2009 Mar;276(5):1221-32.
[41]Klinakis A,Szabolcs M,Chen G,et al.Igflr as a therapeutic target in a mouse model of basal-like breast cancer.Proc Natl Acad Sci U S A.2009 Feb 17;106(7):2359-64.
[42]Araki W,Kume H,Oda A,et al.IGF-1 promotes beta-amyloid production by a secretase-independent mechanism.Biochem Biophys Res Commun.2009 Feb 27;380(1):111-4.
[43]Descamps G,Gomez-Bougie P,Venot C,et al.A humanised anti-IGF-1R monoclonal antibody(AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45.Br J Cancer.2009 Jan 27;100(2):366-9.
[44]Yin S,Zhou X,Peng T,et al.Expression and clinical significance of insulin like growth factor-1 protein in nasopharyngeal carcinoma.Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.2008 Oct;22(19):874-7.
[45]Broughton S,Partridge L.Insulin/IGF-like signalling,the central nervous system and aging.Biochem J.2009 Feb 15;418(1):1-12.
[46]Rikhof B,de Jong S,Suurmeijer AJ,et al.The insulin-like growth factor system and sarcomas.J Pathol.2009 Mar;217(4):469-82.
[47]Sivakumar R,Koga H,Selvendiran K,et al.Autocrine loop for IGF-Ⅰ receptor signaling in SLUG-mediated epithelial-mesenchymal transition.Int J Oncol.2009 Feb;34(2):329-38.
[48]Franz CK,Federici T,Yang J,et al.Intraspinal cord delivery of IGF-Ⅰ mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS.Neurobiol Dis.2009 Mar;33(3):473-81.
[50]de Ostrovich KK,Lambertz I,et al.Paracrine overexpression of insulin-like growth factor-1 enhances mammary tumorigenesis in vivo.Am J Pathol.2008 Sep;173(3):824-34.
[51]Eleswarapu S,Gu Z,Jiang H.Growth hormone regulation of insulin-like growth factor-Ⅰ gene expression may be mediated by multiple distal signal transducer and activator of transcription 5 binding sites.Endocrinology.2008 May;149(5):2230-40.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |